RNF169

Across TCGA pan-cancer cohorts, RNF169 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RNF169’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RNF169 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RNF169 is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

CCRCC, PDAC, and LSCC are the cancer types where RNF169 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNF169 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	+0.189	<.001	9	view →
PDAC	Male	All	−0.394	<.001	7	view →
LSCC	Male	All	+0.237	<.001	4	view →
LUAD	Female	All	−0.126	.003	3	view →
OV	All	All	−0.417	.021	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RNF169–CCRCC

Open the CCRCC breakdown →